Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026

Same author

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026

Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026

Same author

Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides.

JAMA dermatology·2026

Same author

Clinicopathologic features of systemic ALK-negative anaplastic large cell lymphoma with TP53 deletion.

American journal of clinical pathology·2026

Same author

Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: what's new for investigational agents?

Expert opinion on investigational drugs·2026

Search research articles

Related Experiment Video

Updated: Nov 15, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Targeted based therapy in nodal T-cell lymphomas.

Dai Chihara¹, Milos Miljkovic², Swaminathan P Iyer³

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dchihara@mdanderson.org.

|March 5, 2021

Summary

Targeted therapies show promise for T-cell lymphomas (TCL), with brentuximab vedotin and ALK inhibitors effective in specific subtypes. However, monotherapy targeting common genetic alterations offers limited durable responses, necessitating combination treatments for T-cell lymphomas.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Experiment Videos

Last Updated: Nov 15, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Area of Science:

Oncology
Hematology
Molecular Biology

Background:

T-cell lymphomas (TCL) are diverse neoplasms of mature T lymphocytes.
Recent biological insights have improved TCL classification, but clinical trials lag.
Biomarker-driven treatments like brentuximab vedotin and ALK inhibitors show efficacy in specific TCL subtypes.

Purpose of the Study:

To review the current status and role of targeted therapies in nodal T-cell lymphomas.
To highlight the potential and limitations of biomarker-driven treatments in TCL.
To discuss the need for combination therapies in T-cell lymphomagenesis.

Main Methods:

Literature review of targeted therapies in nodal T-cell lymphomas.
Analysis of biomarker-driven treatment efficacy and limitations.
Discussion of ongoing clinical trials for combination therapies.

Main Results:

Brentuximab vedotin is standard for CD30+ TCL and relapsed/refractory ALCL.
ALK inhibitors show responses in ALK+ ALCL.
Monotherapies targeting PI3K/mTOR, JAK/STAT, and epigenetic regulators yield unsatisfactory and non-durable responses.

Conclusions:

Targeted therapies offer specific treatment avenues in TCL, but monotherapy limitations persist.
Combination treatments are crucial for addressing the multistep nature of T-cell lymphomagenesis.
Further research is needed to optimize biology/biomarker-driven strategies in TCL.